X-Therma Launches Cold Chain Platform for Cell Therapies

X-Therma has announced the commercial launch of its XT-NoVo and TimeSeal platform, an end-to-end biopreservation and transport system designed to preserve highly sensitive biologics at sub-zero temperatures without freezing, using a non-toxic antifreeze molecule.¹

The company says the integrated platform can safely extend the storage and transport window of cell-based therapies from the industry's current standard of two to four hours under hypothermic conditions to up to five days.

"The commercial launch of XT-NoVo and TimeSeal represents a milestone in making fresh, off-the-shelf therapies a global reality," said Xiaoxi Wei, MD, co-founder and chief executive officer of X-Therma, in a release.¹

The stakes for solving this problem are considerable, as the complexity of maintaining rigorous temperature stability is cited as a primary obstacle that hinders the global cell and gene therapy cold chain logistics market.²

How Does the XT-NoVo and TimeSeal System Work?

The XT-NoVo and TimeSeal system is built around two integrated components. The XT-NoVo Biopreservation Solution is a fully defined, serum-free, and non-toxic sub-zero formulation that uses proprietary peptoid technology inspired by natural antifreeze proteins to prevent ice formation at −5°C.¹ Unlike conventional cryopreservation protocols, the formulation contains no dimethyl sulfoxide (DMSO) — a solvent used in biopreservation but known to carry cytotoxicity concerns — and is designed to preserve the structural and functional integrity of cells, primary tissues, organoids, and three-dimensional constructs.¹

The companion, TimeSeal Smart Sensored Transporter, is a lightweight, modular shipping platform that requires no external power or perfusion systems. Embedded smart sensor technology provides real-time temperature tracking and stability assurance throughout transit — a critical feature given how vulnerable advanced therapeutics are to even brief temperature excursions in the field.¹

Together, the two components are designed to function as an integrated cold chain solution from manufacturing site to clinical administration, eliminating the handoff vulnerabilities that have made last-mile distribution a persistent risk point for biologics shippers.

Why Does XT-NoVo and TimeSeal Matter to the Industry?

The significance of this announcement is rooted in a fundamental incompatibility that has existed since the first cell therapies reached commercialization: living medicines expire on rigid schedules, but supply chains do not operate on rigid schedules.

While short-term storage at temperatures of 2–8°C is feasible for some apheresis material, extending the shelf life outside of that limited window leads to significant metabolic decline — and the logistical complexities of cryopreservation introduce their own risks, as unforeseen disruptions in cold chain logistics and a lack of proven expertise could compromise cellular viability, jeopardizing product, treatment efficacy and patient safety.³

The cell and gene therapy supply chain demands coordination across numerous variables — when the patient should come to the clinic, apheresis collection timing, manufacturing site availability, and delivery windows — with a just-in-time process necessary at nearly every stage.

"By safely extending the shelf life of highly sensitive cell-based biologics from hours to days, we are fundamentally removing the time, geographic and logistical barriers that have historically bottlenecked regenerative medicine,” said Wei.¹ “This end-to-end platform simplifies logistics and introduces a highly reliable, cost-effective cold chain that will ensure life-saving advanced therapies safely reach patients worldwide."

A five-day viability window, if validated at commercial scale, would give distributors, CDMOs, and clinical sites significantly more lead time to manage scheduling, absorb transit delays, and reach patients beyond the major medical centers.

How Broad Is the Platform's Applicability?

According to Neil Warma, a board member at X-Therma, the platform offers non-frozen preservation across cell lines, primary cells, and complex tissue-on-chip models — a breadth he says provides the operational backbone needed to scale the next generation of regenerative medicine.¹

Additionally, X-Therma previously received FDA Breakthrough Device designation for its XT-ViVo and TimeSeal system for human kidney preservation, and has established an operational presence in Austria to support European market development.

Where Does This Leave the CGT Cold Chain?

The commercial launch arrives at a moment when the broader industry is actively assessing cold chain infrastructure. With a promising clinical pipeline in front of the CGT market, the pressure to build distribution networks that are both reliably temperature-controlled and commercially scalable is more acute than ever. X-Therma's platform represents a compelling entry into that conversation.

References

1. X-Therma Inc. "X-Therma Launches XT-NoVo® & TimeSeal® Platform: Shattering Cold Chain Barriers for On-Demand Regenerative Medicine." PR Newswire, June 10, 2026. https://www.prnewswire.com/news-releases/x-therma-launches-xt-novo--timeseal-platform-shattering-cold-chain-barriers-for-on-demand-regenerative-medicine-302794477.html
2. "Cell & Gene Therapy Cold Chain Logistics Market Outlook 2021–2031: Global Revenues Set to Reach $4.47 Billion by 2031." GlobeNewswire, January 22, 2026. https://www.globenewswire.com/news-release/2026/01/22/3223564/28124/en/Cell-Gene-Therapy-Cold-Chain-Logistics-Market-Outlook-2021-2031-Global-Revenues-Set-to-Reach-4-47-Billion-by-2031.html
3. OrganaBio. "Cryopreservation for Critical Starting Material Products: Benefits of Effective Cold Chain Management." April 15, 2024. https://www.organabio.com/cryopreservation-for-critical-starting-material-products-benefits-of-effective-cold-chain-management/